Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Malignant Germ-Cell Tumours of the Adult Male

Presenters

Lekha Nair

Citation

Annals of Oncology (2020) 31 (suppl_6): S1319-S1324. 10.1016/annonc/annonc357

Authors

L.M. Nair1, K.M. Jagathnath Krishna2, A. Kumar1, S. Mathews1, J. Joseph1, F.V. James1

Author affiliations

  • 1 Genitourinary Clinic, RCC - Regional Cancer Centre, Thiruvananthapuram, 695011 - Trivandrum/IN
  • 2 Epidemiology & Biostatisticss, Regional Cancer Centre Thiruvananthapuram/Trivandrum, 695011 - Trivandrum/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 208P

Background

Germ cell tumours of testis is the most common cancer in young men in the western world. India has the lowest incidence globally and hence Indian data is sparse. We report the outcomes of patients with non-seminomatous germ cell tumours of testis treated at a tertiary cancer centre in South India over a period of ten years.

Methods

Patients with a histopathological diagnosis of non-seminomatous germ cell tumours of testis from Jan 1, 2006 to Dec 31, 2016 were included in the study. Patient demographics, tumour characteristics and treatment details were retrieved from case records. Kaplan-Meier method was used to estimate progression-free survival and overall survival. Cox regression model was used to analyse the prognostic factors.

Results

One hundred and nineteen patients with non-seminomatous germ cell tumours of testis of testis were included in the study. The median follow-up was 81 months. The estimated four-year overall survival and progression-free survival was 87.1% and 84.5% respectively. The four-year overall survival for good, intermediate and poor-risk groups was 93.6%,87.5% and for 52.6% respectively. The progression-free survival at four years was 91.4%, 87.8% and 47.4% for good, intermediate and poor-risk groups respectively. The presence of non-pulmonary visceral metastasis and biochemical response after chemotherapy were significant factors for overall survival and progression free survival in multivariate cox proportional hazards regression.

Conclusions

The survival figures are comparable to the rest of the world except in the poor prognostic risk group. The inferior survival noticed in this group of patients may be due to the lack of good salvage procedures. High dose chemotherapy with stem cell support may be considered more often for this group of patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.